Diabetic retinopathy, also known as diabetic eye disease, is when damage occurs to the retina due to diabetes. It is an ocular affirmation of diabetes, a systemic disease, which affects up to 80 percent of all patients who have had diabetes for 10 years or more.
Approximately one-third of diabetic people develop some degree of diabetes-related eye damage, or retinopathy. This complication, which is characterised by damage to the retina provoked by microvascular changes resulting from diabetes, can lead to partial vision loss and more often than not to blindness.
Around 10% of patients diagnosed with diabetes suffer from severe visual impairment. On a global scale this translates to millions of people!
Blind diabetics and those losing their vision have to continue to live independently. Apoema® has opted to assist blind diabetics by printing Braille on the primary packaging of its Diabetes Pro Care product line. Braille is the internationally widespread reading and writing system for blind and partially sighted people.
While the European Union has issued directives to print Braille on nutraceutical and pharmaceutical labels, no such directive exists for cosmetics or cosmeceuticals within the European Union or any other country in the World.
Apoema®, however, strongly opines that blind diabetics and diabetic patients with impaired vision deserve correlative independence with cosmeceutical products and for that principle Apoema® is a vanguard to this initiative.